VERIFIEDET Markets·21 May 2026positive

Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?

AI Summary

·Sun Pharma is anticipated to achieve double-digit revenue growth in Q4FY26.
·Growth drivers include strong performance in speciality drugs, domestic formulations, and emerging markets.
·EBITDA growth is expected to be supported by a diversified global business momentum.